What’s new

• Management set a new revenue target of ₹800-850 crore for FY28, building on its ₹1,000 crore aspiration for FY29.
• The company is shifting its biosimilar pipeline focus from Alteplase to Pembrolizumab (a Keytruda generic).
• Regulated-market registrations in Germany for its products are expected within months.

Why it matters

Kwality is moving from a record ₹503 crore revenue year into a phase of aggressive, capital-intensive expansion. The pivot to Pembrolizumab, a high-value oncology drug, and the capex plan signal a strategic bet on complex biologics. The new FY28 guidance implies nearly 70% growth from FY26, making execution on this pipeline critical.

What we’re watching

• Timelines for the Erythropoietin biosimilar regulatory submission by year-end.
• Progress on the Algeria joint venture funding clinical trials for the Pembrolizumab generic.
• Margin trajectory towards the stated 30% EBITDA target.

The full read

Kwality Pharmaceuticals finished a record year with ₹503 crore in revenue and ₹67 crore profit, but the call was about the future. Management unveiled a new FY28 target of ₹800-850 crore, implying roughly 70% growth in two years, and set an EBITDA margin goal of 30% for FY29. To get there, it's committing ₹260-270 crore in capex to oncology capacity, hormones, and biosimilars. The biggest move is a pipeline pivot: Kwality dropped Alteplase to develop a Pembrolizumab generic, a far bigger commercial prize. An Algeria JV will help fund the trials. On the commercial side, German registrations are imminent. The playbook is clear: use cash from a strong existing business to fund a push into complex biologics.

Primary source: BSE · NSE